RougeTx

RougeTx is a biotech developing first-in-class small-molecule therapies for vascular diseases caused by pericyte dysfunction.

Health and bio

RougeTx raised $58M in a Series A round announced October 6, 2026, according to finsmes.com. Investors in that round: Angelini Ventures, BioGeneration Ventures, Auréa, Epidarex Capital, European Investment Bank Group, Kerna Ventures, Kurma Partners, p53, ROM Utrecht Region, Vesalius Biocapital Partners.

Team

• EV
  Edward van Wezel Board member
• ER
  Elizabeth Roper Board member
• HB
  Hadrien Bouchez Board member
• RH
  Regina Hodits Board member
• SV
  Stephane Verdood Board member

Raise history

1. October 6, 2026
   Series A · $58M
   AAngelini Ventures (lead), BBioGeneration Ventures (lead), AAuréa, EEpidarex Capital, EEuropean Investment Bank Group, KKerna Ventures, KKurma Partners, Pp53, RROM Utrecht Region, VVesalius Biocapital Partners
   Source: finsmes.com
2. May 22, 2024
   Website created

Investors

• AAngelini Ventures
• AAuréa
• BBioGeneration Ventures
• EEpidarex Capital
• EEuropean Investment Bank Group
• KKerna Ventures
• KKurma Partners
• Pp53
• RROM Utrecht Region
• VVesalius Biocapital Partners

Related bio health companies

• SSunfox$7M · Oct 7, 2026
• AAlteogen$150M · Oct 6, 2026
• SSynvareOct 6, 2026
• SSuperMush$3M · Oct 6, 2026
• AArcheon Medical$9M · Oct 6, 2026
• KKymaThera$80M · Oct 6, 2026
• AArboretum$30M · Oct 6, 2026
• CCureMeAbroad$1.1M · Oct 6, 2026

Every amount links to the page it came from. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/rougetx.